

Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease

NCT06876363

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Ensoma
Enrollment	15 participants

Key Eligibility Criteria

Inclusion (8)

- Male
 - e 18years of age during dose escalation, then e 3 months of age during dose expansion
 - Diagnosis of X-CGD with DHR+ cells d 5% and a pathogenic mutation in the CYBB gene
 - History of at least 1 severe infection requiring medical intervention or chronic inflammatory disorder
 - Does not have a suitable, available, and willing human leukocyte antigens (HLA)-matched (10/10) related donor
- ... and 3 more (see full listing online)

Exclusion (8)

- Active bacteremia or fungemia
 - History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
 - History or clinical evidence of any medical or social issues likely to put the participant at additional risk or to interfere with study conduct
 - History of HSCT or granulocyte transfusions
 - Known hypersensitivity to elements in the treatment regimen
- ... and 3 more (see full listing online)

Locations (9 total)

University of California, Los Angeles, Los Angeles, California, United States
University of California, San Francisco, San Francisco, California, United States
Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States
... and 6 more locations